Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07.
Our annual meeting of shareholders (the “Meeting”) was held on August3, 2017. A quorum was present. At the Meeting, our shareholders elected Meenu Chhabra and Jeffery W. Kelly, Ph.D., to serve as ClassII directors to serve on our board of directors until the annual meeting of shareholders to be held in 2020. Prior to the meeting, Helen Boudreau withdrew from consideration for election to the Company’s Board following her decision to accept employment as the Company’s Chief Financial Officer and subsequent resignation from the Board. The tabulation of votes with respect to the election of such directors was as follows:
| For | Withheld | BrokerNonVote | |
|
Meenu Chhabra |
20,382,001 | 824,386 | 2,012,819 |
|
Jeffery W. Kelly, Ph.D. |
20,146,510 | 1,059,877 | 2,012,819 |
In addition, our shareholders ratified the appointment of PricewaterhouseCoopersLLP as our independent registered public accounting firm for the fiscal year ending December31, 2017. The tabulation of votes with respect to these proposals was as follows:
| For | Against | Abstain | |
|
Ratification of our Independent Registered Public Accounting Firm |
23,153,057 | 7,737 | 58,412 |
About Proteostasis Therapeutics, Inc. (NASDAQ:PTI)
Proteostasis Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models. Using this platform, it has identified a new class of small molecules, amplifiers that modulate proteins in the proteostasis network. It is developing and intend to commercialize its lead amplifier of CFTR protein, PTI-428, to improve CFTR protein function. It also focuses on developing PTI-NC-733, PTI-130, Usp14 program and unfolded protein response (UPR) program. PTI-130 is a small molecule amplifier.
